Carolina Escobar, MD
Hematology & Oncology · Dallas, TXNPI 1306047428
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,540 of the $61,927 with a category attached, or 81.6%. Gilead accounts for 76.6% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $53,489 and has fallen 99.2% since, to $423 in 2025. Among hematology & oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 99 payments — averaging $625.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$47K
- Seagen Inc.$13K
- Astellas Pharma US Inc$384
- AbbVie$355
- Bristol Myers Squibb$322
- Incyte Corporation$168
- plus $766 from 16 others
Across 53 payments — averaging $2015.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$100K
- Merck$7K
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$50,54082%
- Travel & lodging$8,40714%
- Food & beverage$2,1133%
- Education$5671%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 34 | $47,410 |
| Seagen Inc. | 14 | $12,522 |
| Astellas Pharma US Inc | 5 | $384 |
| AbbVie | 14 | $355 |
| Bristol Myers Squibb | 2 | $322 |
| Incyte Corporation | 4 | $168 |
| Janssen Scientific Affairs, LLC | 3 | $131 |
| ADC Therapeutics America, Inc. | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 2 | $63 |
| Johnson & Johnson | 2 | $61 |
| Sanofi | 2 | $60 |
| Karyopharm Therapeutics Inc. | 2 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $41 |
| Novartis | 2 | $40 |
| Merck | 2 | $37 |
| AstraZeneca | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Amgen | 1 | $21 |
| GSK | 1 | $20 |
| 180 Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,927 in reported general payments places this provider in the 90th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Dallas
- Edward PearsonDallas$900K
- Christopher MaiselDallas$713K
- Ashwani AgarwalDallas$275K
- Katherine WangDallas$188K
- Houston HolmesDallas$178K
- Benjamin KitchensDallas$177K
- Farrukh AwanDallas$138K
- Dai Chu LuuDallas$90K
- Luis PineiroDallas$86K
- Joan SchillerDallas$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.